2. Academic Validation
  3. ADAR2 editing enzyme is a novel human immunodeficiency virus-1 proviral factor

ADAR2 editing enzyme is a novel human immunodeficiency virus-1 proviral factor

  • J Gen Virol. 2011 May;92(Pt 5):1228-1232. doi: 10.1099/vir.0.028043-0.
Margherita Doria 1,  Sara Tomaselli 2,  Francesca Neri 1,  Silvia Anna Ciafrè 3,  Maria Giulia Farace 3,  Alessandro Michienzi 3,  Angela Gallo 2
Affiliations

Affiliations

  • 1 Laboratory of Immunoinfectivology, Children's Hospital Bambino Gesù, 00165 Rome, Italy.
  • 2 RNA Editing Laboratory, Department of Pediatric Hematology/Oncology, IRCCS Ospedale Bambino Gesù, Rome, Italy.
  • 3 Department of Experimental Medicine and Biochemical Sciences, University of Rome 'Tor Vergata', 00133 Rome, Italy.
PMID: 21289159 DOI: 10.1099/vir.0.028043-0
Abstract

The adenosine deaminases acting on RNA (ADAR) enzymes catalyse conversion of adenosine to inosine in dsRNA. A positive effect of ADAR1 on human immunodeficiency virus type 1 (HIV-1) replication has recently been reported. Here, we show that another ADAR Enzyme, ADAR2, positively affects the replication process of HIV-1. We found that, analogously to ADAR1, ADAR2 enhances the release of progeny virions by an editing-dependent mechanism. However, differently from the ADAR1 Enzyme, ADAR2 does not increase the infectious potential of the virus. Importantly, downregulation of ADAR2 in Jurkat cells significantly impairs viral replication. Therefore, ADAR2 shares some but not all proviral functions of ADAR1. These results suggest a novel role of ADAR2 as a viral regulator.

Figures